

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported) August 30, 2019**

---

**XOMA CORPORATION**

(Exact name of registrant as specified in its charter)

---

**000-14710**  
(Commission  
File Number)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**52-2154066**  
(IRS Employer  
Identification No.)

**2200 Powell Street, Suite 310, Emeryville, California**  
(Address of principal executive offices)

**94608**  
(Zip Code)

**Registrant's telephone number, including area code (510) 204-7200**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of each class</u>	<u>Trading Symbol(s)</u>	<u>Name of each exchange on which registered</u>
<b>Common Stock, par value \$0.0075 per share</b>	<b>XOMA</b>	<b>The Nasdaq Global Market</b>

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

---

**Item 8.01 Other Events.**

On August 30, 2019, XOMA Corporation (the “Company”) posted its updated corporate presentation on the Company’s website that includes an additional slide, included as exhibit 99.1 hereto.

**Cautionary Statements**

*Certain statements in the attached exhibit are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding: future monetization opportunities, active transactions with significant financial implications, collaborations poised for significant financial contribution, our library of value-generating assets, future potential for milestone and royalty payments, the potential of our unique antibody discovery engine, the ability of our partners and their licensees to successfully develop their pipeline programs, the productivity of acquired assets that may not fulfill our revenue forecasts, upcoming internal milestones and value catalysts, our future cash needs, our strategy for value creation, and other statements that relate to future periods. These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for companies engaged in the development of new products in a regulated market. Potential risks to XOMA meeting these expectations are described in more detail in XOMA’s most recent filing on Form 10-K for the year ended December 31, 2018 and in other more recent SEC filings. Consider such risks carefully when considering XOMA’s prospects. Any forward looking statements represent XOMA’s views only as of the date of this presentation and should not be relied upon as representing its views as of any subsequent date. XOMA disclaims any obligation to update any forward-looking statement, except as required by law.*

**Item 9.01 Financial Statements and Exhibits.**

<u>Exhibit</u>	<u>Description</u>
99.1.	<a href="#"><u>Corporate Presentation Slide</u></a>

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

XOMA CORPORATION

Date: August 30, 2019


/s/ Thomas Burns

Thomas Burns

Senior Vice President, Finance and Chief Financial Officer

# XOMA'S PORTFOLIO KEY HIGHLIGHTS

Does not include certain assets subject to confidentiality agreements

 <span style="margin-left: 100px;">ABOUT US ▾</span> <span style="margin-left: 50px; background-color: #0070C0; color: white; padding: 2px 5px;">ROYALTY PORTFOLIO</span> <span style="margin-left: 50px; color: #0070C0;">OPPORTUNITIES</span>			
PARTNER	ASSET NAME	TARGET	ROYALTY RATE
Bayer	BAY1213790	Factor Xia	Low single-digit
Bayer	BAY1831865	Factor Xia	Low single-digit
Bayer/Aronora	AB023 (xisomab 3G3)	Factor XI	Low single-digit
Incyte	INCAGN1876	GITR	Mid-single-digit
Incyte	INCAGN1949	OX-40	Mid-single-digit
Incyte	INCAGN02390	TIM-3	Low to mid-single-digit
Incyte	INCAGN2385	LAG-3	Low to mid-single-digit
Janssen Biotech	JNJ-64407564	GPRC5D	0.75%
Janssen Biotech	JNJ-63723283	PD-1	0.75%
Janssen Biotech	JNJ-55920839	IFN	0.75%
Janssen Biotech	JNJ-63709178	CD123xCD3	0.75%
Janssen Biotech	JNJ-63998081	PSMA	0.75%
Janssen Biotech	JNJ-64232025	CD154	0.75%
Merck	MK-4830	ILT-4	Low single-digit
Novartis	CFZ533 (iscalimab)	CD-40	Mid-single-digit to mid-teens
Novartis	VPM087 (gevokizumab)	IL-15	High single-digit to mid-teens

 <span style="margin-left: 100px;">ABOUT US ▾</span> <span style="margin-left: 50px; background-color: #0070C0; color: white; padding: 2px 5px;">ROYALTY PORTFOLIO</span> <span style="margin-left: 50px; color: #0070C0;">OPPORTUNITIES</span>			
PARTNER	ASSET NAME	TARGET	ROYALTY RATE
Novartis	NI5793	TGFβ	Mid-single digit to low teens
Takeda	TAK-079	CD-38	4%
Takeda (Molecular Templates)	TAK-169	CD-38	4%
Adhera	PRESTALIA	FDC perindopril arginine & amlodipine	Up to double digit
Alligator Bioscience (Janssen)	JNJ-64457107	CD40	0.75%
Aronora	AB002 (ProCase)	E-WE thrombin	Low single-digit
Aronora	AB054	Factor XII	Low single-digit
AVEO	ficlatuzumab	Anti-HGF	Low single-digit
Compugen	COM902	TIGIT	Low single-digit
Margaux Biologics	XOMA 629	BPI	Low to mid-single-digit
Monopar (Formerly Tactic and Attenuon)	MNPR-101	uPAR antibody	None
Ology	XOMA 3A8, XOMA B, and XOMA E toxin serotypes	Botulism	15%
Rezolute	RZ358	INSR	High single-digit to mid-teens
Rezolute	AB101	Insulin & Kalikrein Inhibitor	Low single-digit
Rezolute	RZ402	Insulin & Kalikrein Inhibitor	Low single-digit
Sesen (Formerly Eleven Bio & Viventia)	Vicinium	EpCAM antigens	2.50%

> \$1 billion in potential milestones

